A long time ago HA Irinotecan was said to be worth $200m a year in profit to acl if successful. If one puts a p/e of 20 to that, then that's $4b (or around $12 a share).
However if HA Irinotecan is used as a first line treatment, then it'll be worth more.
BUT..... HA Irinotecan is just one drug from the HyACT platform. So a p/e higher than 20 could (or should) be used.
I would suggest that $200m a year profit is probably too high an expectation, but then a p/e of 20 is too low. So maybe $12 a share is a fair value (if successful and when the money starts rolling in).
I've held acl a long time and HyACT has always been our possible golden goose. I certainly won't be selling for a long time (although I'm free carried so that makes it easier).
cheers
- Forums
- ASX - By Stock
- TSN
- targets
targets, page-5
-
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable